SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cadus Pharmaceutical Corp. (KDUS) -- Ignore unavailable to you. Want to Upgrade?


To: scaram(o)uche who wrote (625)11/16/2001 3:18:03 PM
From: Tomato  Read Replies (1) | Respond to of 1833
 
4. experienced management Does that definition include a CEO who is aware of the potential milestone and royalty income? [g]



To: scaram(o)uche who wrote (625)11/16/2001 11:54:04 PM
From: Tomato  Read Replies (1) | Respond to of 1833
 
6. eccentric billionaire shareholder determined to maximize his gains and take minority shareholders on the ride with him

7. rapacious market makers whose huge spreads discourage would-be buyers to purchase, thus leaving plenty of opportunity for mokes like us to get in at bargain prices

8. secret plan by CEO to sell to TELK (who saw Harmon's musings a while back and decided there was no reason not to act now) by the end of Dec. at a ratio that values the stock at 3 times market value



To: scaram(o)uche who wrote (625)11/17/2001 11:59:27 AM
From: Luke  Read Replies (1) | Respond to of 1833
 
Could you be describing Arena as well? Research premium is something like $30M, w/ $240M in cash (hence no advanced products).

Do you have an opinion on ARNA? Seem to have interesting technology and are tackling projects that at least many pharmas try or want to do. Is ARNA missing out much by not having the (ex?-)Cadus yeast technology?